Role of Mesenchymal Stromal Cells as Therapeutic Agents: Potential Mechanisms of Action and Implications in Their Clinical Use
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Due to the great therapeutic interest that involves the translation of mesenchymal stromal cells (MSCs) into clinical practice, they have been widely studied as innovative drugs, in order to treat multiple pathologies. MSC-based cell therapy involves the administration of MSCs either locally or systemically into the receptor body where they can traffic and migrate towards the affected tissue and participate in the process of healing. The therapeutic effects of MSCs compromise of different mechanisms such as the functional integration of differentiated MSCs into diseased host tissue after transplantation, their paracrine support, and their impact on the regulation of both the innate and the acquired immune system. Here, we establish and provide recent advances about the principal mechanisms of action through which MSCs can perform their activity and effect as a therapeutic tool. The purpose of this review is to examine and discuss the MSCs capacity of migration, their paracrine effect, as well as MSC-mediated modifications on immune cell responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications
Wang, Y., Chen, X., Cao, W., & Shi, Y. (2014) · Nature Immunology · doi:10.1038/ni.3002 · Cited by 1,452
Waterman, R. S., Tomchuck, S. L., Henkle, S. L., & Betancourt, A. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010088 · Cited by 1,238
Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases
Shi, Y., Wang, Y., Li, Q., Liu, K., Hou, J., Shao, C., & Wang, Y. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0023-5 · Cited by 1,223 · cited 1×
“They are involved in immunoregulation by interacting with both myeloid and lymphoid cells of innate and adaptive immune systems, making no-immune activation [24,25].”
BackgroundMesenchymal Stem Cells for Regenerative Medicine
Han, Y., Li, X., Zhang, Y., Han, Y., Chang, F., & Ding, J. (2019) · Cells · doi:10.3390/cells8080886 · Cited by 1,093
Viswanathan, S., Shi, Y., Galipeau, J., Krampera, M., Leblanc, K., Martin, I., Nolta, J., Phinney, D. G., & Sensebe, L. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.08.002 · Cited by 839
Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation
Prockop, D. J., & Youn Oh, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.211 · Cited by 816 · cited 3×
“Despite the fact that the homeostatic and immunomodulatory activity of MSCs were thought to be reliant on MSC cell number, it has been seen that it depends more on the paracrine factors these cells secrete, also known as ‘’secretome”, which is produced once MSCs are activated [49,53].”
BackgroundMorrison, T. J., Jackson, M. V., Cunningham, E. K., Kissenpfennig, A., McAuley, D. F., O’Kane, C. M., & Krasnodembskaya, A. D. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0170oc · Cited by 796
Jackson, M. V., Morrison, T. J., Doherty, D. F., McAuley, D. F., Matthay, M. A., Kissenpfennig, A., O'Kane, C. M., & Krasnodembskaya, A. D. (2016) · Stem Cells · doi:10.1002/stem.2372 · Cited by 582 · cited 2×
“Regarding the transfer of mitochondria from MSCs EVs, it was demonstrated that there is an increase of phagocytic activity after mitochondrial transfer from MSC to innate immune cells [79].”
BackgroundHEO, J. S., CHOI, Y., KIM, H.-S., & KIM, H. O. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2413 · Cited by 495 · cited 1×
“Therefore, selection of an adequate cell source for their clinical use should ideally be based on their logistical, practical, and functional behavior [10].”
BackgroundMelief, S. M., Zwaginga, J. J., Fibbe, W. E., & Roelofs, H. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0184 · Cited by 442
Immunomodulatory effects of mesenchymal stromal cells-derived exosome
Chen, W., Huang, Y., Han, J., Yu, L., Li, Y., Lu, Z., Li, H., Liu, Z., Shi, C., Duan, F., et al. (2016) · Immunologic Research · doi:10.1007/s12026-016-8798-6 · Cited by 343 · cited 6×
“Moreover, T cell proliferation and their differentiation into helper T cells, like Th1 and Th17, can be inhibited by MSC secretome which includes HLA-G, galectins, and IDO among other molecules, enabling macrophages to produce transforming growth factor-β (TGF-β) and promoting T regulatory Figure 2.”
BackgroundInfluential
Cited by
Alvites, R., Branquinho, M., Sousa, A. C., Lopes, B., Sousa, P., & Maurício, A. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020381 · Cited by 174
“Alternatively, EVs, especially exosomes, can also act as RNA transferors between cells, thus regulating gene expression and indirectly and therapeutically influencing different clinical scenarios [13].”
BackgroundMethodInfluentialChow, L., Johnson, V., Impastato, R., Coy, J., Strumpf, A., & Dow, S. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0092 · Cited by 161
García-Bernal, D., García-Arranz, M., Yáñez, R. M., Hervás-Salcedo, R., Cortés, A., Fernández-García, M., Hernando-Rodríguez, M., Quintana-Bustamante, Ó., Bueren, J. A., García-Olmo, D., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650664 · Cited by 138
Controversies regarding transplantation of mesenchymal stem cells
Velikova, T., Dekova, T., & Miteva, D. G. (2024) · World Journal of Transplantation · doi:10.5500/wjt.v14.i2.90554 · Cited by 12
Metadata
- Authors
- Jimenez-Puerta, G., Marchal, J., López-Ruiz, E., & Gálvez-Martín, P.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-02-06
- Volume
- 9
- Issue
- 2
- Pages
- 445
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W3004936872
- Cited by
- 106
- References
- 11
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.